

Q2 Result with SPI

Sun Pharmaceutical Industries Limited

Regd Office: Sun Pharma Advanced Research Centre, Akota Road, Akota, Vadodara-390015

Corporate Office : Acme Plaza, Andheri-Kurla Road, Andheri (E), Mumbai - 400059

Unaudited Financial Results combined with SPI for the quarter ended 30th September

	Quarter ended		Growth % QoQ	H 30.09.02
	30.09.03	30.09.02		
Total Income	2616.4	2190.1	19.5	.
Sales	2526.8	2166.4	16.6	.
Domestic	1999.9	1826.8	9.5	:
Exports	526.9	339.6	55.2	.
Share of Income From Firm	0.0	0.0		.
Other Income	88.5	11.8		.
Net Interest Income	1.1	11.9		.
Total Expenditure	1828.9	1549.5	18.0	:
(Increase)/Decrease in Stock in Trade	(125.8)	(32.3)		(
Material Cost	1023.5	854.7		.
Staff Cost	154.3	98.1		.
Indirect Taxes	303.8	269.1		.
Research & Development	139.5	74.8		.
Other Expenditure	333.6	285.1		.
Profit Before Depreciation and Tax	787.5	640.6	22.9	.
Depreciation / Amortisation	57.8	49.7		.
Profit Before Tax	729.7	590.9		.
Provision for Tax	30.4	43.7		.
Deferred Tax	26.9	14.1		.
Profit After Tax	672.4	533.1	26.1	.
Share of Minority Partner	11.9	0.0		.
Net Profit	660.5	533.1	23.9	.
Paid-up Share Capital				
Equity Shares - Face Value Rs. 5	463.8	467.9		
Preference Shares - Face Value Re. 1	157.0	0.0		

Notes:

1. The above numbers combined with the results of SPI (*), are furnished for information and better comparison.
2. Sales for the quarter, include Rs. 126.2 Million of inter-unit sales of bulk drugs for manufacturing formulations.

Mumbai, 21st October 2003

Total Sales	2526.8	2166.4	16.6	
Domestic	1999.9	1826.8	9.5	
Formulation	1570.8	1458.6	7.7	
Bulk	429.1	365.6	17.4	
Others	0.0	2.6		
Exports	526.9	339.6	55.2	
Formulation	176.2	96.3	83.0	
Bulk	343.0	242.3	41.6	
Others	7.7	1.0		
Business wise Break up of Sales	2526.8	2166.4	16.6	
Formulations	1747.0	1554.9	12.4	
Bulk	772.1	607.9	27.0	
Others	7.7	3.6	113.9	
Net Interest Income	1.1	11.9	-90.8	
Gross Interest Income	9.5	12.8	-25.8	
Gross Interest Expenses	8.4	0.9	833.3	
R&D Expenditure as % of Sales	10.0%	9.5%		
Total R&D Expenditure	253.5	205.5	23.4	
Capital	114.0	130.7	-12.8	
Revenue	139.5	74.8	86.5	